Key result
Early menopause proteomic signature is linked to up to ~46% higher cardiometabolic and mortality risk.
Why the study?
Is a proteomic signature of early menopause associated with increased cardiometabolic and mortality risk in post-menopausal women?
Cohort (n=14,774)
Yes
Is a proteomic signature of early menopause associated with increased cardiometabolic and mortality risk in post-menopausal women?
A proteomic signature associated with early menopause predicts long-term cardiometabolic and mortality risks in post-menopausal women, modestly improving clinical prediction models.
Background: Early menopause is associated with an increased risk of cardiovascular disease among women. However, the mechanisms underlying this association are not well-understood. We aimed to comprehensively evaluate the proteomic architecture of early menopause and examine the association of a derived proteomic signature with cardiometabolic and mortality risk. Methods: This cohort study included 14,774 post-menopausal women from the UK Biobank. Multivariate-adjusted linear regression was used to identify proteins associated with early menopause (defined as natural or surgical menopause occurring before 45 years of age). A proteomic signature was constructed using least absolute shrinkage and selection operator (LASSO) regression. Associations with incident cardiometabolic diseases [cardiovascular disease (CVD, which included coronary artery disease, stroke, heart failure, atrial fibrillation, and peripheral artery disease), diabetes, chronic kidney disease (CKD), and metabolic dysfunction-associated fatty liver disease (MAFLD)] and mortality were assessed using multivariable-adjusted Cox models. Results: Among 14,774 postmenopausal women (mean age 59.8 years), 2,964 (20.1%) experienced early menopause. Of 2,911 proteins examined, 67 were significantly associated with early menopause after correcting for multiple testing, mainly involved in pathways and processes related to cellular adhesion, extracellular matrix organization, and tissue remodeling. The proteomic signature of early menopause was associated with greater cardiometabolic risk and mortality (HR ranged from 1.14 to 1.46), with most associations remaining statistically significant even after adjustment for self-reported history of early menopause. Addition of the proteomic signature to clinical models modestly improved their predictive abilities (ΔHarrell’s C-index ranged from +0.003 to +0.013). Conclusions: Early menopause is associated with significant changes in the circulating proteome, which may in turn mediate its relationship with long-term cardiometabolic and mortality risks. Further research is needed to understand the mechanisms underlying these associations and to identify potential novel pathways for personalized prevention and therapeutics in this population.
No takes yet. Share an insight, caveat, or question.
Qian et al. (2026) conducted a cohort in Early menopause (n=14,774). Proteomic signature of early menopause vs. Normal menopause was evaluated on Incident cardiometabolic diseases and mortality (HR 1.14 to 1.46). A proteomic signature of early menopause was associated with greater cardiometabolic risk and mortality (HR ranged from 1.14 to 1.46).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: